A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1 – BUSINESS We are a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. We believe our zinc finger epigenetic regulators are ideally suited to potentially address devastating neurology disorders and our capsid engineering platform has demonstrated the ability to expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system, or CNS, in preclinical studies. Our Core Neurology Programs Our neurology development is focused on two innovative areas: (i) development of epigenetic regulation therapies to treat serious neurological diseases and (ii) development of novel engineered adeno-associated virus, or AAV, capsids to deliver our therapies to the intended neurological targets.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 33M | 58M | 176M | 111M | 111M | 118M |
| Net Income | -109M | -98M | -258M | -192M | -178M | -121M |
| EPS | $-0.45 | $-0.49 | $-1.48 | $-1.25 | $-1.23 | $-0.90 |
| Free Cash Flow | -76M | -67M | -246M | -244M | -257M | 155M |
| ROIC | -97.2% | -360.7% | -261.2% | -65.2% | -47.5% | -24.3% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | 3.46 | 0.99 | 0.91 | 0.92 | 0.89 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -109M | -104M | -274M | -201M | -183M | -130M |
| Operating Margin | -331.6% | -179.9% | -155.5% | -180.8% | -165.6% | -109.6% |
| ROE | -1744.5% | -185.4% | -311.1% | -65.2% | -47.5% | -24.3% |
| Shares Outstanding | 336M | 200M | 174M | 154M | 145M | 134M |
SANGAMO THERAPEUTICS, INC passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +74.7%.
SANGAMO THERAPEUTICS, INC (SGMO) has a 5-year average return on invested capital (ROIC) of -45.7%. This is below average and may indicate limited pricing power.
SANGAMO THERAPEUTICS, INC (SGMO) has a market capitalization of $86M. It is classified as a small-cap stock.
SANGAMO THERAPEUTICS, INC (SGMO) does not currently pay a regular dividend.
SANGAMO THERAPEUTICS, INC (SGMO) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
SANGAMO THERAPEUTICS, INC (SGMO) reported annual revenue of $58 million in its most recent fiscal year, based on SEC EDGAR filings.
SANGAMO THERAPEUTICS, INC (SGMO) has a net profit margin of -169.4%. The company is currently unprofitable.
SANGAMO THERAPEUTICS, INC (SGMO) generated $-67 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
SANGAMO THERAPEUTICS, INC (SGMO) has a debt-to-equity ratio of 3.46. This indicates higher leverage, which may increase financial risk.
SANGAMO THERAPEUTICS, INC (SGMO) reported earnings per share (EPS) of $-0.49 in its most recent fiscal year.
SANGAMO THERAPEUTICS, INC (SGMO) has a return on equity (ROE) of -185.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for SANGAMO THERAPEUTICS, INC (SGMO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
SANGAMO THERAPEUTICS, INC (SGMO) has a book value per share of $0.11, based on its most recent annual SEC filing.